Andrew Dunbar, MD
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Attending, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Dunbar is a laboratory-based physician-scientist and principal investigator of a translational research lab within the Department of Hematopoietic Biology and Malignancy (HBM) program at MD Anderson Cancer Center. His work focuses on the study of clonal evolution, fibrosis progression, and targeted therapy resistance in myeloproliferative neoplasms (MPN) and other myeloid blood cancers. He aims to use animal models of human disease along with state-of-the-art, multimodal, next-generation sequencing techniques applied to patient samples collected at MD Anderson to uncover novel pathobiologic vulnerabilites that are amenable to therapeutic intervention. Ultimately, he hopes the findings from this work will translate into innovative drug therapies that improve clinical outcomes for people afflicted by these conditions.
Clinical Interests
Myeloproliferative Neoplasms Acute Myeloid Leukemia Clonal Hematopoiesis Myelodysplastic Syndromes Chronic Myeloid Leukemia
Education & Training
Degree-Granting Education
| 2012 | New York Medical College, Valhalla, NY, USA, MD, Medicine |
| 2006 | Vanderbilt University, Nashville, TN, USA, BM/BS, Biology and Music |
Postgraduate Training
| 2016-2023 | Post-doctoral Fellowship, Laboratory of Dr. Ross Levine, Memorial Sloan Kettering Cancer Center, New York, NY |
| 2015-2018 | Hematology/Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY |
| 2012-2015 | Internal Medicine Residency, New York Presbyterian | Weill Cornell Medical Center, New York, NY |
Board Certifications
| 2018 | Medical Oncology, American Board of Internal Medicine (ABIM) |
| 2015 | Internal Medicine, American Board of Internal Medicine (ABIM) |
Experience & Service
Academic Appointments
Assistant Attending, Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY, 2020 - 2023
Instructor, Department of Leukemia - Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2018 - 2020
Other Appointments/Responsibilities
Institutional Panel Member, National Comprehensive Cancer Network (NCCN), New York, NY, 2020 - 2023
Honors & Awards
| 2021 | Sawiris Foundation Award, Memorial Sloan Kettering Cancer Center |
| 2019 | William Raveis Charitable Fund Fellow, Physician-Scientist Training Award, Damon Runyon Cancer Research Foundation |
| 2018 | Next Gen Innovator, HemeOnc Today |
| 2017 | Young Investigator Award, American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation |
| 2017 | Clinical and Translational Cancer Research Fellowship, American Association for Cancer Research (AACR) |
| 2016 | F30 Predoctoral National Research Service Award (T32-CA009207), National Institute of Health |
| 2012 | Cor et Manus Award for Extraordinary Community Service, New York Medical College |
| 2007 | Young Investigator Travel Award, American Society of Hematology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC. Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clin Cancer Res 30(3):586-599, 2024. e-Pub 2023. PMID: 37992313.
- Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell Rep 43(1):113608, 2024. e-Pub 2023. PMID: 38117649.
- Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernandez-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov. e-Pub 2024. PMID: 38230747.
- Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv 8(2):429-440, 2024. PMID: 37871309.
- Fidler TP, Dunbar A, Kim E, Hardaway B, Pauli J, Xue C, Abramowicz S, Xiao T, O'Connor K, Sachs N, Wang N, Maegdefessel L, Levine R, Reilly M, Tall AR. Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis. Nat Cardiovasc Res 3(1):60-75, 2024. e-Pub 2024. PMID: 38362011.
- McCarter JGW, Nemirovsky D, Famulare CA, Farnoud N, Mohanty AS, Stone-Molloy ZS, Chervin J, Ball BJ, Epstein-Peterson ZD, Arcila ME, Stonestrom AJ, Dunbar A, Cai SF, Glass JL, Geyer MB, Rampal RK, Berman E, Abdel-Wahab OI, Stein EM, Tallman MS, Levine RL, Goldberg AD, Papaemmanuil E, Zhang Y, Roshal M, Derkach A, Xiao W. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv 7(17):5000-5013, 2023. PMID: 37142255.
- Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, Park Y, Karzai A, Xiao W, Zaroogian Z, O'Connor K, Mowla S, Gobbo F, Verachi P, Martelli F, Sarli G, Xia L, Elmansy N, Kleppe M, Chen Z, Xiao Y, McGovern E, Snyder J, Krishnan A, Hill C, Cordner K, Zouak A, Salama ME, Yohai J, Tucker E, Chen J, Zhou J, McConnell T, Migliaccio AR, Koche R, Rampal R, Fan R, Levine RL, Hoffman R. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood 141(20):2508-2519, 2023. PMID: 36800567.
- Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol 98(1):79-89, 2023. e-Pub 2022. PMID: 36251406.
- Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033-1062, 2022. PMID: 36075392.
- Verachi P, Gobbo F, Martelli F, Martinelli A, Sarli G, Dunbar A, Levine RL, Hoffman R, Massucci MT, Brandolini L, Giorgio C, Allegretti M, Migliaccio AR. The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 low Mice. Front Oncol 12:853484, 2022. e-Pub 2022. PMID: 35392239.
- Farina M, Bernardi S, Polverelli N, D'Adda M, Malagola M, Bosio K, Re F, Almici C, Dunbar A, Levine RL, Russo D. Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells 10(10), 2021. e-Pub 2021. PMID: 34685741.
- Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, Famulare CA, Goldberg AD, Cai SF, Dunbar A, Epstein-Peterson Z, Menghrajani KN, Glass JL, Taylor J, Viny AD, Giralt SS, Gyurkocza B, Shaffer BC, Tamari R, Levine RL, Tallman MS, Stein EM. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. Am J Hematol 96(5):E171-E175, 2021. e-Pub 2021. PMID: 33650111.
- Dunbar A, Park Y, Levine R. Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):237-251, 2021. e-Pub 2021. PMID: 33641866.
- Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, Wills J, Kelly D, Farina M, Cordner KB, Park Y, Kishore S, Juluru K, Iyengar NM, Levine RL, Zehir A, Park W, Khorana AA, Soff GA, Mantha S. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood 137(15):2103-2113, 2021. PMID: 33270827.
- Dunbar A, Levine RL. "Interferon" with MPN hematopoietic stem cells. Blood 137(16):2129-2130, 2021. PMID: 33885710.
- Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(9):1248-1269, 2020. PMID: 32886902.
- Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood 136(1):61-70, 2020. PMID: 32430500.
- Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica 105(3):e91-e94, 2020. e-Pub 2019. PMID: 31413098.
- Billon P, Nambiar TS, Hayward SB, Zafra MP, Schatoff EM, Oshima K, Dunbar A, Breinig M, Park YC, Ryu HS, Tschaharganeh DF, Levine RL, Baer R, Ferrando A, Dow LE, Ciccia A. Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. Cell Rep 30(10):3280-3295.e6, 2020. PMID: 32160537.
- Bernardi S, Farina M, Zanaglio C, Cattina F, Polverelli N, Schieppati F, Re F, Foroni C, Malagola M, Dunbar AJ, Russo D. ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial. Case Rep Hematol 2020:2795656, 2020. e-Pub 2020. PMID: 32148977.
- Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica 104(7):1378-1387, 2019. e-Pub 2018. PMID: 30523054.
- Dunbar A, Nazir A, Levine R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol 77:14.40.1-14.40.19, 2017. e-Pub 2017. PMID: 28640953.
Grant & Contract Support
| Title: | Investigating High-Risk Epigenetic Modifying Alterations on JAK2VF Dependency and Fibrotic Progression in Myeloproliferative Neoplasms (MPNs) |
| Funding Source: | NIH/NHLBI |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified May 03, 2024